Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Self-complementary adeno-associated virus (scAAV) vectors can significantly minimize the vector load required to achieve sustained transgene expression. In this study, transcriptional regulatory elements were systematically screened to produce constitutive and liver-specific scAAV factor IX (FIX) expression cassettes. In addition, optimization of GC content, cis- regulatory elements, and codon usage in the human FIX (hFIX) transgene increased expression 4-20-fold. A vector was developed that was capable of expressing high FIX levels in comparison with the single-stranded (ss) AAV vector used in a recent clinical trial. The ssAAV and scAAV vectors display different transgene expression and genome stability patterns in the liver, as determined by immunohistochemical staining, in situ messenger RNA (mRNA) hybridization and vector genome quantitation. The ssAAV2 vector promoted strong FIX expression in only a subset of hepatocytes. The scAAV2-hFIX vector showed widespread ( approximately 80% of hepatocytes), moderate FIX expression levels similar to normal livers with correction of coagulation function in FIX-deficient mice. The ability of low dose scAAV-FIX vectors to achieve near-physiological expression may circumvent inflammatory responses in the liver. In addition to providing an improved scAAV vector for potential application in future hemophilia B clinical trials and liver-directed gene delivery, these studies underscore the need for rigorous analysis and optimization of vector genome cassettes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The bGHpolyA turned out to be the strongest for the FIX gene expression, outperforming other polyA sequences such as the synthetic polyA, mouse β-globin pA, rabbit β-globin pA, and H4-based pA [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Especially, the strong MVM intron-1 of the viral capsid protein (VP-1) of only 67-to-97 bp can increase the transcript expression by 10× [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Strikingly, introducing the Minute virus of mice (MVM) intron between promoter and transgene has been reported to increase 80-fold of transgene expression in liver cells compared to intron-null AAV [24].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [24]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Self-citationFisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Self-citationCodon usage limitation in the expression of HIV-1 envelope glycoprotein
Haas, J., Park, E.-C., & Seed, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00482-7 · Cited by 532
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Cited by
Items 101–158 of 158
Kao, C., Lin, C., Yu, I., Tao, M., Wu, H., Shi, G., Yang, Y., Kao, J., & Lin, S. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0792 · Cited by 17
Analysis of F9 point mutations and their correlation to severity of haemophilia B disease
Hamasaki‐Katagiri, N., Salari, R., Simhadri, V. L., Tseng, S. C., Needlman, E., Edwards, N. C., Sauna, Z. E., Grigoryan, V., Komar, A. A., Przytycka, T. M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02848.x · Cited by 18
Guenzel, A. J., Hillestad, M. L., Matern, D., & Barry, M. A. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.012 · Cited by 17
“The transthyretin (TTR) promoter in combination with an intron from the small minute virus of mice (Wu et al., 2008) was a kind gift from Dr. Paul E. Monahan (University of North Carolina at Chapel Hill).”
BackgroundMethodShort regulatory DNA sequences to target brain endothelial cells for gene therapy
Graßhoff, H., Müller‐Fielitz, H., Dogbevia, G. K., Körbelin, J., Bannach, J., Vahldieck, C., Kusche-Vihrog, K., Jöhren, O., Müller, O. J., Nogueiras, R., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211039617 · Cited by 18
Sun, J., Hua, B., Chen, X., Samulski, R. J., & Li, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.016 · Cited by 16
“Both constructs are driven by the liverspecific transthyretin (TTR) promoter, as described previously.(24) Mouse FVIIa was packaged into an AAV9 capsid.”
BackgroundSelf-citationKaiser, R. A., Weber, N. D., Trigueros‐Motos, L., Allen, K. L., Martinez, M., Cao, W., VanLith, C. J., Hillin, L. G., Douar, A. M., González‐Aseguinolaza, G., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12392 · Cited by 18
“The aim of this study therefore was to evaluate the transduction profile and transgene expression efficiency in the Pah mouse model of PKU of two distinct Anc80 AAV vectors expressing PAH, under the albumin enhancer and alpha 1 anti-trypsin (A1AT) promoter, constructed either with or without a minute virus of mice (MV…”
MethodOsman, E., Evans, V., Graham, I. R., Athanasopoulos, T., McIntosh, J., Nathwani, A. C., Simons, J. P., Dickson, G., & Owen, J. S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.043 · Cited by 16
Ko, A., Jin, D., Cho, S. Y., Park, S. W., Przybylska, M., Yew, N. S., Cheng, S. H., Kim, J.-S., Kwak, M. J., Kim, S. J., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.02.001 · Cited by 17
“[33]) NC_001510.”
Lavender, H., Brady, K., Burden, F., Delpuech-Adams, O. E., Denise, H., Palmer, A., Perkins, H., Savic, B., Scott, S., Smith‐Burchnell, C., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05357-11 · Cited by 14
“AAV-8-mediated transgene expression has been shown to persist in the murine livers for a minimum of 120 days (40, 43).”
BackgroundPortal Vein Delivery of Viral Vectors for Gene Therapy for Hemophilia
Sherman, A., Schlachterman, A., Cooper, M., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Herzog, R. W., & Nichols, T. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-761-7_27 · Cited by 13
“Use of cDNAs optimized for mammalian codon usage can further improve therapeutic expression [14, 18, 22, 23].”
BackgroundImproved AAV9-based gene therapy design for SURF1-related Leigh syndrome with minimal toxicity
Ling, Q., Rioux, M., Higgs, H., Hu, Y., Dwyer, S. E., & Gray, S. J. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101554 · Cited by 11
“14,15 Additionally, we designed the weakest construct with the JeT promoter and a synthetic poly(A) (SpA) 16 to drive the lowest expression of h SURF1 .”
Lopes‐Pacheco, M., Kitoko, J. Z., Morales, M. M., Petrs‐Silva, H., & Rocco, P. R. M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.09.015 · Cited by 11
Tissue blood volumes and weights in adult beagle dogs.
Cuddihy, R. G., Hall, R. P., HOBBS, C. H., Boecker, B. B., & Muggenburg, B. A. (1972) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 10
Jiang, F., Zhang, C., Liu, W., Liu, F., Huang, H., Tan, Y. F., & Qin, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1301915 · Cited by 9
“As a result, the design of recombinant AAV (rAAV) vectors involves removing most of the viral genome, leaving behind only the necessary elements, such as promoters, transgenes, and poly A tails, for gene therapy applications (Wu et al., 2008).”
BackgroundMembrane fusion FerA domains enhance adeno-associated virus vector transduction
Zhang, X., Anthony, B., Chai, Z., Dobbins, A. L., Sutton, R. B., & Li, C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119906 · Cited by 10
“hFIX protein concentration in the plasma was measured by enzyme-linked immunosorbent assay (ELISA) as previously described [44].”
MethodSanchez–Daza, A., Li, C., Andrews, B. A., Asenjo, J. A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.043 · Cited by 9
Self-citationGene therapy for hemophilia: advancing beyond the first clinical success
Monahan, P. E., & Gui, T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c1a1 · Cited by 9
Self-citationRosenberg, J. B., De, B. P., Greco, A., Gorman, N., Kooner, V., Chen, A., Yost-Bido, M., Muñoz‐Zuluaga, C., Kaminsky, S. M., Rostami, M., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.192 · Cited by 8
Ziraldo, M., Bidart, J. E., Prato, C. A., Tribulatti, M. V., Zamorano, P. I., Mattion, N., & D’Antuono, A. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.591019 · Cited by 7
“Firstly, to enhance the expression of the O1/Campos capsid proteins, we placed the P12A3C transgene under the transcriptional control of an optimized pCMV, which comprises the pCMV and the human chimeric β-globin/IgG intron regulatory element, which is well known to produce strong intron-mediated enhancement-related e…”
BackgroundEvans, V. C., Graham, I. R., Athanasopoulos, T., Galley, D. J., Jackson, C. L., Simons, J. P., Dickson, G., & Owen, J. S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.04.015 · Cited by 6
“Vector productivity can also be increased by codon optimization [54] and, for relatively short sequences, by the use of a self-complementary (scAAV) vector [54-56].”
BackgroundTransgene Site-Specific Integration: Problems and Solutions
Bire, S., & Rouleux‐Bonnin, F. (2012) · Topics in current genetics · doi:10.1007/978-94-007-4531-5_1 · Cited by 8
Schroeder, J. A., Chen, J., Chen, Y., Cai, Y., Yu, H., Mattson, J. G., Monahan, P. E., & Shi, Q. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004071 · Cited by 7
Self-citationLong-term expression of canine FVIIa in hemophilic dogs
Margaritis, P. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.01.040 · Cited by 6
“For instance, enhanced expression can be a result of an improved delivery vector and/or expression cassette that includes the promoter element(s), intron, as well as the codon optimization FVIIa transgene itself, strategies that have been effective in other gene transfer approaches [19,20].”
MethodMerberg, D., Moreland, R. J., Su, Z., Ли, Б., Crooker, B., Palmieri, K. J., Moore, S. W., Melber, A., Boyanapalli, R., Carey, G. J., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2402503 · Cited by 5
“…all transgene plasmids contained itRs sequences derived from aaV2, a synthetic muscle promoter sPc5-12 [19], minute virus of the mouse (MVM) intron [20], WPRe3 [21] and a synthetic polyadenylation sequence [22]. the Dph-cRe04 and the csk-sh5 transcriptional enhancers were inserted 5 ′ to the…”
BackgroundDiep, T., Zhou, W., Reyes, R. E., Nitzahn, M., Day, I. L., Makris, G., Lueptow, L., Zhuravka, I., Bakshi, S., Gangoiti, J., et al. (2025) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2025.102470 · Cited by 2
“45 In studies conducted by Monahan 46 evaluating and comparing small promoters for liver-directed expression in vivo , TTR provided the highest expression and thus was incorporated into our vector.”
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Optimization of miR-22 expression cassette for rAAV delivery on diabetes
Li, Y., Du, W., Zheng, Z., Wang, L., Xiao, L., Yang, Q., Hao, Q., Zhou, J., Du, J., Li, J., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-021-00063-y · Cited by 4
Pushing the Right Buttons: Improving Efficacy of Therapeutic DNA Vectors
Hacobian, A., & Hercher, D. (2017) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2017.0353 · Cited by 6
“90 Similar observations were made with exogenous factor IX in liver cells in vivo , 91 demonstrating tissue-independent functionality.”
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS)
Pagovich, O. E., Stiles, K. M., Camilleri, A. E., Russo, A. R., Nag, S., & Crystal, R. G. (2021) · Leukemia · doi:10.1038/s41375-021-01400-4 · Cited by 4
Gene-based continuous expression of FVIIa for the treatment of hemophilia
Margaritis, P. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/269 · Cited by 5
Viral vectors engineered for gene therapy
Lundstrom, K. H. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.005 · Cited by 5
Artemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
“A scAAV vector with an mTTR promoter provided higher levels of FIX expression in vivo [265].”
Adeno-associated Virus-Mediated Gene Delivery Across the Blood-Brain Barrier
Yao, Y., & Bei, F. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_4 · Cited by 4
Expression Cassette Design and Regulation of Transgene Expression
Keravala, A., & Gasmi, M. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000363 · Cited by 5
Design of Muscle Gene Therapy Expression Cassette
Lai, Y., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_8 · Cited by 3
Sun, J., Chen, X., Chai, Z., Niu, H., Dobbins, A. L., Nichols, T. C., & Li, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.880763 · Cited by 4
“All human FV DNA sequences (Figures 1, 2) were synthesized by GenScript (Piscataway, NJ, United States) and driven by the chicken beta actin (CBA) promoter (Figure 1) or the liver-specific transthyretin (TTR) promoter (500 bp including an MVM intron) and fused with BGH polyA (230 bp), as described previously (24).”
MethodSelf-citationXu, R., Diep, T., Singh, K., Bakshi, S., Wu, G. F., Lu, M., Tang, G., Schwerk, J., Sun, Q., Häberle, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.045 · Cited by 3
Yuan, H.-K., Wu, X., Liu, H., & Chang, L. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.140 · Cited by 2
Bio-Production of Adeno-Associated Virus for Gene Therapy
Donohue, N., Keogh, N., Boi, S., & Barron, N. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_11 · Cited by 1
Yang, Z., Yamaguchi, Y., Lyu, X., Haris, A., Christofi, E., Tsunaka, Y., Torisu, T., & Uchiyama, S. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104255 · Cited by 1
Factor IX Deficiency or Hemophilia B: Clinical Manifestations and Management
Kasthuri, R. S., Roberts, H. R., & Monahan, P. E. (2014) · Wiley eBooks · doi:10.1002/9781118833391.ch5 · Cited by 1
Self-citationThe State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Hemophilia Gene Therapy: An Overview
Lillicrap, D. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch40
Quan, J. (2012) · DukeSpace (Duke University)
Apolipoproteins A-I and A-V as gene therapeutic targets to intervene in lipid metabolism
Vaessen, S. F. C. (2009) · UvA-DARE (University of Amsterdam)
Gene Therapy for Bleeding Disorders
Monahan, P. E., & Abajas, Y. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_29
Self-citationAAV-Nrf2 Mediated Rescue of Oxidative Stress in Mouse Models
Liang, K. J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tmc2-r921
[A review of gene therapy for Duchenne muscular dystrophy].
Dong, Q.-C., Chen, H., & Jin, X. (2018) · PubMed · doi:10.7499/j.issn.1008-8830.2018.08.017
Evaluation of AAV Vector Constructs to Titrate Transgene Expression
Peralta, M. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/58pe-4t91
Optimizing gene therapy for infant mice with citrullinemia type 1
Bazo, A. (2023) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/67875
Approches de thérapies géniques pour des maladies neuromusculaires
Moulay, G. (2010) · theses.fr (ABES) · doi:10.70675/e7c5d58ez3cc2z4a72z8d92z6b13cb1ea30c · Cited by 1
CTCF regulates wild-type and recombinant AAV gene expression by shaping viral chromatin
Larsen, C. I. S., Abrahams, R. R., Guertler, R., Wilion, E. M., Erata, E., Sykes, Z. H., Stoica, L., Thirumoorthy, G., Sinha, D., Rai, R., et al. (2026) · PLoS Pathogens · doi:10.64898/2026.06.03.729793 · Cited by 1
Molina, A., Trigueros‐Motos, L., Molina, M., Martínez-García, J., Palomo, L., Pérez, G., Odriozola, L., Gázquez, C., Tamarit, B., Faassen, M. V., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001027 · Cited by 1
“[25] A small intron derived from minute virus of mice (MVM) [26,27] was introduced downstream of the promoter and upstream of the transgene sequence in both AAV-co-hBSEP constructs, generating AAV-A1AT-MVM-co-hBSEP and AAV-imPr-MVM-co-hBSEP plasmids, respectively (Figure 1A).”
Jahnz, H., Hamann, M. V., Kim, H. O., Sun, Y., Salazar-Quiroz, N. A., Zhu, L., Leddy, S. M., Swaiba, U. E., Schneider, C., Foth, D., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261487919
Development of AAV vectors for the therapy of autoimmune and inflammatory diseases
Li, C., Hirsch, M. L., & Samulski, R. J. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_11
Self-citation
Metadata
- Authors
- Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Monahan, Paul E
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 16
- Issue
- 2
- Pages
- 280-289
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1980491559
- Cited by
- 153
- References
- 50
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 11 · 2019: 5 · 2018: 6 · 2017: 10 · 2016: 10 · 2015: 5 · 2014: 11 · 2013: 6 · 2012: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3171 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01-HL66973, P01HL066973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- self-complementary AAV vectors, hemophilia B, factor IX, liver-directed gene delivery, cis-regulatory elements, codon usage, GC content, hepatocyte transduction
- MeSH terms
- Dependovirus, Animals, Base Composition, Hemophilia B, Codon, Factor IX, Genetic Vectors, Humans, Immunohistochemistry, Liver, Male, Mice, Inbred C57BL, Transcription, Genetic, Blotting, Southern, Genetic Therapy, Gene Expression, In Situ Hybridization, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.